Image 01 Image 03

Le·gal In·sur·rec·tion

/var/www/vhosts/legalinsurrection.com/httpdocs/wp-content/themes/bridge-child/readFeeds.incFALSE

LATEST NEWS

Events are moving quickly, converging on the subterfuge and subversion by Team Obama. Team Obama was behind the Flynn set up. Obama was in on it, and so were others. How deep Obama's own hands go into the spying on the Trump transition remains to be seen, but Obama's staged "leak" criticizing DOJ is a tell.

On Wednesday, Mike LaChance wrote a post at Legal Insurrection discussing the shocking letter to the NY Times written by long-time journalist Martin Tolchin saying that Tara Reade's accusations against Joe Biden should not be investigated:  “I don’t want justice, whatever that may be. I want a win, the removal of Donald Trump from office, and Mr. Biden is our best chance.” As extreme as the letter is, I believe there's a tactical method in Tolchin's madness, and a reason the Times published it.

The European Union wants to restart its tourism sector as the spread of coronavirus recedes, a newly released policy document shows. A strategy document compiled by the European Commission, EU's executive arm, titled “Europe needs a break” recommends gradual lifting of border restrictions between member states to promote inner-European travel, the news agency Reuters reported.

Gibson's Bakery v. Oberlin College has received enormous media attention, and even *a few* posts here. Another Oberlin College case we have followed involved an expelled Oberlin College male student (we'll call him "John Doe No. 1") who alleged that the Oberlin College sexual assault hearing process was so rigged against men that it had a 100% conviction rate for cases that went to hearing, at least during the period of time relevant to that case. Now there is another lawsuit by a different student raising similar issues of an allegedly biased campus process.

Hackers with links to Iran have targeted a U.S. drugmaker working on a potential coronavirus treatment, Reuters news agency reported on Friday. The US drugmaker Gilead Sciences, whose antiviral drug remdesivir has shown promising results in treating coronavirus patients, came repeatedly under cyber attack from servers based in Iran in recent weeks, media reports reveal.